PMID- 37470600
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231102
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 19
IP  - 3
DP  - 2023 Apr-Jun
TI  - Multiple myeloma: Unveiling the survival data with different lines of treatments.
PG  - 720-724
LID - 10.4103/jcrt.jcrt_1426_21 [doi]
AB  - PURPOSE: The incidence of multiple myeloma (MM) is rising and there are fewer 
      Indian studies; a comprehensive research of MM patients' survival data in a 
      real-world population is needed. This study aims to analyze the survival status 
      of MM patients with different treatment regimens along with its correlation to 
      other parameters such as treatment-free interval (TFI) and time-to-next treatment 
      (TTNT). MATERIALS AND METHODS: This was a retrospective observational study, done 
      in the department of oncology, at a tertiary care hospital in Kerala, from August 
      2019 to July 2020, to analyze the survival data in patients diagnosed with MM 
      from 2015 to 2019. The effectiveness endpoints include time-to-event analyses 
      such as TTNT and TFI. After receiving various therapy regimens, the survival 
      rates were analyzed; the Kaplan-Meier estimator was used to determine the 
      cumulative survival. The correlations between overall survival (OS) and duration 
      of therapy, TFI, TTNT, and other parameters were calculated using the Karl 
      Pearson's correlation coefficient. RESULTS: 72 (82.80%) of the patients survived 
      to the end of the study (OS), with a mean survival time of 4.02 +/- 2.81 years. 52 
      (59.80%) patients had progression-free survival (PFS), while the remaining 35 
      (40.22%) had no significant disease prognosis. Both OS and PFS showed a 
      significant positive correlation (P > 0.05) with TTNT and TFI. CONCLUSIONS: 
      Completely adherent chemotherapy for 1 year can promise a survival time not <2 
      years. Longer TFI resulted in better OS and PFS. Extending the duration of the 
      second LOT correlated with the better OS and PFS.
FAU - Kurian, Helan
AU  - Kurian H
AD  - Department of Pharmacy Practice, Nirmala College of Pharmacy, Muvattupuzha, 
      Kerala, India.
FAU - Abraham, Suja
AU  - Abraham S
AD  - Department of Pharmacy Practice, MGM Silver Jubilee College of Polytechnic and 
      Pharmaceutical Sciences, Ernakulam, Kerala, India.
FAU - Antony, Arpith
AU  - Antony A
AD  - Department of Pharmacy Practice, Nirmala College of Pharmacy, Muvattupuzha, 
      Kerala, India.
FAU - Jiju, Jeeva Ann
AU  - Jiju JA
AD  - Department of Pharmacy Practice, Nirmala College of Pharmacy, Muvattupuzha, 
      Kerala, India.
FAU - Thomas, Timy
AU  - Thomas T
AD  - Department of Pharmacy Practice, Nirmala College of Pharmacy, Muvattupuzha, 
      Kerala, India.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
SB  - IM
MH  - Humans
MH  - *Multiple Myeloma/drug therapy
MH  - Prognosis
MH  - Progression-Free Survival
MH  - Survival Analysis
MH  - Retrospective Studies
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
OTO - NOTNLM
OT  - Lines of treatment
OT  - multiple myeloma
OT  - overall survival
OT  - progression-free survival
OT  - time-to-next treatment
OT  - treatment-free interval
COIS- None
EDAT- 2023/07/20 13:07
MHDA- 2023/07/20 13:08
CRDT- 2023/07/20 09:29
PHST- 2023/07/20 13:08 [medline]
PHST- 2023/07/20 13:07 [pubmed]
PHST- 2023/07/20 09:29 [entrez]
AID - JCanResTher_2023_19_3_720_335485 [pii]
AID - 10.4103/jcrt.jcrt_1426_21 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2023 Apr-Jun;19(3):720-724. doi: 10.4103/jcrt.jcrt_1426_21.